| Molecular formula | C16H22N6O4 |
|---|
| Molecular weight | 362.38 g/mol |
|---|
| Registered trials | 21 |
|---|
| PubChem CID | 638678 |
|---|
What protirelin is
Protirelin is a synthetic version of thyrotropin-releasing hormone (TRH), a small peptide compound identified by PubChem CID 638678. No product label details were available for this entry, so approved indications, mechanism wording, and brand names cannot be summarized here.
Trial footprint
Protirelin has been studied across 21 registered clinical trials. Sampled studies illustrate the range of research interest: a completed trial examined antenatal TRH in women in premature labor to help prevent lung disease in preterm infants, a completed trial looked at body weight regulation in patients with narcolepsy, and a phase 2 trial evaluating synthetic TRH for cancer-related fatigue was terminated. These examples show the breadth of conditions researchers have explored with this compound, but they do not establish that protirelin is effective or approved for any of them.
FAQ
Protirelin is a synthetic form of thyrotropin-releasing hormone (TRH), a small peptide compound. It is identified in chemical databases by PubChem CID 638678. No label data was available in this record to describe an approved mechanism or indication.
This record does not include label data confirming FDA approval details, such as indications or brand names. Any approved status or use should be confirmed through official prescribing information rather than research trial data alone.
There are 21 registered clinical trials associated with protirelin. Sampled trials span topics such as preterm labor, narcolepsy, and cancer-related fatigue, with statuses ranging from completed to terminated.
Trial samples show research into antenatal use for preventing lung disease in preterm infants, body weight regulation in narcolepsy patients, and cancer-related fatigue. One of these trials, the phase 2 fatigue study, was terminated rather than completed. These examples reflect areas of investigation, not confirmed treatment uses.
No adverse event report data was available in this record to summarize reported side effects. Anyone considering protirelin should look to official label information or a healthcare provider for safety details.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: ClinicalTrials.gov PubChem
Updated 2026-09-19